Clinical trials: Pituitary Tumor
Pituitary Adenomas, Prolactinomas
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, and select medical therapies…
- Trial name
- NCT00939523
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cedars-Sinai Medical Center
Pituitary Adenoma
Prediction of Sphenoid Septation in MRI Compared With CT and Intraoperative Findings During Endoscopic Pituitary Adenoma Surgery
To investigate whether MRI is able to predict the exact anatomy and topography of the sphenoid sinus and its relationship to the sellar, parasellar und paraclinoid region and where CT yields more detailed information for the…
- Trial name
- Scope (NCT03624114)
- Testing
- comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery
- Where
- 2 sites in Malaysia, Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Pituitary Neoplasms
Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection
Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into the trachea after the operation.
- Trial name
- NCT05088252
- Testing
- Desflurane, Propofol
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Beijing Tiantan Hospital
Pituitary Tumor, Surgery
Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery
Pituitary tumours have an estimated prevalence of 20% in the general population and the number of clinically relevant pituitary adenomas is increasing with time.
- Conditions
- Pituitary Tumor, Surgery, Olfactory Nerve Injuries
- Trial name
- NCT03773705
- Testing
- Electrocautery versus scalpel
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Healthy, Pituitary Disease
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities.
- Conditions
- Healthy, Pituitary Disease, Thyroid Disease
- Trial name
- NCT00054756
- Testing
- TRH (Thyrotropin Releasing Hormone)
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Surgery
Mode of Ventilation and Bleeding During Transsphenoidal Surgery
The risk of bleeding is important during transsphenoidal surgery. This study aims to find if the ventilation mode, controlled pressure and controlled volume, modifies the risk of bleeding.
- Trial name
- Vent-Hyp (NCT01891838)
- Testing
- Volume controlled ventilation, Pressure-controlled ventilation
- Where
- France
- Volunteers
- 101 people
- Sponsor
- Hopital Foch
Pituitary Adenoma
Transsphenoidal Extent of Resection Study
The purpose of this research study is to compare the extent of resection (EOR) in patients with nonfunctioning pituitary adenomas undergoing transsphenoidal surgery using a microsurgical technique to those patients who have…
- Trial name
- TRANSSPHER (NCT02357498)
- Testing
- transsphenoidal surgery
- Where
- 7 sites in United States
- Volunteers
- 260 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Acromegaly
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth.
- Trial name
- NCT00171886
- Testing
- Octreotide
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Prolactinoma
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
- Trial name
- NCT03717454
- Testing
- Surgery, Drug treatment
- Volunteers
- 50 people
- Sponsor
- Zhebao Wu
Pituitary Neoplasms, Pituitary Adenoma
Hypofractionated Radiosurgery to Treat Residual/Recurrent Non Secreting Pituitary Adenoma (HYPOADENO)
Single session stereotactic radiosurgery (SRS) is commonly used for patients with non-functioning adenomas. However the SRS can be limited by the proximity of the tumor with the surrounding critical structures (i.e., the optic…
- Trial name
- HYPOADENO (NCT06826170)
- Testing
- hypofractionated radiosurgery
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Brain and Central Nervous System Tumors, Metastatic Cancer
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
- Trial name
- NCT00255671
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Leiomyoma, Laparoscopy
Combined Vaginal Misoprostol and Perivascular Vasopressin
Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal.
- Conditions
- Leiomyoma, Laparoscopy, Uterine Myomectomy
- Trial name
- NCT03815344
- Testing
- Standard, Standard-vaginal misoprostol
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Antonios Likourezos
Pituitary Adenoma, Neuroendocrine Tumors
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early…
- Trial name
- NCT06015802
- Testing
- diagnosed and treated reasonably according to the clinical guidelines and clinical pathways
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Pituitary Adenoma
Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma
Pituitary adenoma can be difficult to cure with approximately a third of patients in contemporary series' undergoing incomplete resection.
- Trial name
- NCT03284775
- Testing
- Intraoperative ultrasound
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University College, London
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts